CCL20 and melanoma: Given the important role of TAMs in the progression of RCC and the reported overexpression of CCR6 by cancer cells and aberrant signaling by its ligand CCL20 in many cancer types including colorectal, pancreatic and melanoma solid tumors [8,9,10,11] as well as the development of anti-cancer therapeutics inhibiting CCR6-CCL20 activity [12], investigation of the involvement and mechanisms of the CCL20-CCR6 axis contributing to the development and progression of renal cell cancer is a worthwhile undertaking.